Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|June 2, 2020
- Pharmaceutical Technology-06-02-2020
- Volume 44
- Issue 6
Triple Shaft Mixer with Powder Induction Manifold
The 600-gallon VersaMix Model VM-600 from Ross is qualified for high-speed subsurface powder induction with a proprietary Ross Solids/Liquid Injection Manifold (SLIM).
The 600-gallon VersaMix Model VM-600 from Ross is qualified for high-speed subsurface powder induction with a proprietary Ross Solids/Liquid Injection Manifold (SLIM). The SLIM function allows for the incorporation of powder or liquid phases into the rotor-stator mix head, causing instant wet-out as it rotates at 3600 RPM.
Available in laboratory sizes up to 4000 gallons, the mixer uses a dual-post triple-shaft design for the processing of substantial powder phases along with an anchor agitator to move the product from the high shear rotor stator head to a high-speed dispersing head, which deagglomerates any remaining fisheyes. The SLIM feature also enables the device to mix large batches and accelerate loading phases.
Articles in this issue
over 6 years ago
What’s Next in Air Transportation for Clinical Trial Logisticsover 6 years ago
2019 Investments Centered around Cell and Gene Therapiesover 6 years ago
Generic Drugs in Spotlight as Pandemic Creates Shortagesover 6 years ago
Are We All In This Together?over 6 years ago
Following Guidelines During a Crisisover 6 years ago
Intelligent Packaging Promotes Interaction with Patientsover 6 years ago
Why Do Disinfectant Residues Matter?over 6 years ago
Formulating for Convenience and Complianceover 6 years ago
Reducing Risk with Abuse‑Deterrent Formulationsover 6 years ago
Better Connected: The Value of Connected Drug DeliveryRelated to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5